Organon & Co. (NYSE:OGN) Raised to “Hold” at TD Cowen

Organon & Co. (NYSE:OGN) was upgraded by research analysts at TD Cowen to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Separately, Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Organon & Co. has an average rating of “Hold” and an average price target of $21.33.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $15.77 on Wednesday. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The company has a market cap of $4.06 billion, a price-to-earnings ratio of 3.13, a PEG ratio of 0.86 and a beta of 0.76. The firm has a 50 day simple moving average of $15.32 and a 200 day simple moving average of $18.24.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business earned $0.78 EPS. Research analysts predict that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Organon & Co.

Several large investors have recently modified their holdings of the company. Prospera Private Wealth LLC acquired a new position in Organon & Co. in the third quarter valued at $25,000. Horizon Bancorp Inc. IN raised its position in shares of Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after acquiring an additional 1,585 shares in the last quarter. William B. Walkup & Associates Inc. acquired a new position in shares of Organon & Co. in the 2nd quarter valued at about $31,000. Versant Capital Management Inc grew its stake in Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after purchasing an additional 1,324 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.